Report No. 029 · Sat, 10 Oct 2026

Startup Scout: Multiply Labs

Pick of the day

Multiply Labs

A San Francisco robotics company that automates the manual steps of biologics manufacturing, starting with cell and gene therapy, inside closed, GMP-compliant robotic systems.

multiplylabs.com

Biotechnology / Pharmaceutical Manufacturing Robotics · San Francisco

Series B · $75M

33/50Scout score

Problem: 7
Traction: 6
Founders: 7
Market: 7
Novelty: 6

Why today

Today's pick is Multiply Labs, the San Francisco robotics company that announced a 75 million dollar Series B on October 6, 2026, led by Patrick Soon-Shiong's NantWorks, with new investors AstraZeneca, Lingotto, Teradyne and Strange Ventures joining returning backers Casdin Capital, Lux Capital, Fifty Years, Ora Global and Founders Fund. Against a thin stretch of fresh funding news that included a roughly four million dollar seed for a Bengaluru wealthtech platform, a ten million dollar Series A for a dermatology-focused patient-access AI, a twenty-two million dollar Series A for a customer-personalization startup and a ninety-seven million dollar round for an energy-efficient chip spinout, Multiply Labs stands out because it spent nine years building toward an actual paying commercial contract in one of the hardest, most capital-intensive corners of biotech before a brand-name strategic investor backed it.

Problem

Cell and gene therapy manufacturing is still largely manual: technicians perform timed, repetitive steps such as cell isolation, activation, transduction and expansion by hand inside cleanrooms, a process that is slow, expensive and prone to batch-to-batch inconsistency. That manual bottleneck caps how many patients a given facility can treat and keeps production costs high enough that many advanced therapies remain limited to wealthy health systems and small patient populations. The same constraint extends to other biologics, including antibodies, viral vectors and mRNA, where manufacturers rely on a patchwork of specialized instruments that were never designed to run as a single automated line.

Product

Multiply Labs builds enclosed, GMP-compliant robotic systems that automate a manufacturer's existing instrument ecosystem rather than replacing it with one proprietary machine, timing and sequencing the repetitive steps technicians currently perform by hand. The company started with cell and gene therapy and says its robotic clusters can cut cost per dose and multiply throughput compared with manual production, though those figures are the company's own claims rather than independently verified results. It is now extending the same closed-system approach to antibody, viral-vector and mRNA manufacturing, aiming to let pharmaceutical and biologics companies run the platform themselves instead of outsourcing production to a contract manufacturer.

Traction

Multiply Labs has raised more than 100 million dollars since its 2016 founding and converted part of that into paying commercial relationships rather than staying research-only. Its first commercial sale was an agreement with Retro Biosciences worth up to 85 million dollars to automate manufacturing for Retro's age-related-disease cell therapies. The company has also struck collaborations with Legend Biotech on cell therapy automation and with Wilson Wolf on automating G-Rex bioreactors, alongside partners including Akron Bio, Charles River, Fedegari and GenScript. Those commercial deals, more than any single disclosed metric, are the clearest evidence that biologics manufacturers are willing to hand production over to Multiply's robots.

Team

Multiply Labs was co-founded in 2016 by chief executive Fred Parietti, who holds a PhD in mechanical engineering from MIT focused on the design and control of autonomous robotic systems, alongside co-founder Alice Melocchi. The company's early capital included a 3.5 million dollar seed round backed by Y Combinator, and it has spent nine years building toward commercial deployment rather than chasing a fast exit. That slow, hardware-heavy path is unusual for a venture-backed startup, but it is also what let the company land a strategic investor of Patrick Soon-Shiong's standing once its first commercial contract was already signed.

Funding

Multiply Labs announced a 75 million dollar Series B on October 6, 2026, led by Patrick Soon-Shiong's NantWorks, the healthcare and technology group the billionaire founded. New investors AstraZeneca, Lingotto, Teradyne and Strange Ventures joined returning backers Casdin Capital, Lux Capital, Fifty Years, Ora Global and Founders Fund. The round brings the company's total funding to more than 100 million dollars since 2016 and gives it a strategic, pharma-adjacent and industrial-automation investor base heading into its push to scale beyond cell and gene therapy into antibodies, viral vectors and mRNA manufacturing.

Competitors

Multiply Labs competes against well-capitalized rivals chasing the same cell and gene therapy automation opportunity. Cellares, which last raised 257 million dollars, offers a modular cGMP platform built around closed, single-use cartridges for industrial-scale manufacturing. London-based Ori Biotech automates and standardizes manufacturing as customers move from preclinical process development to commercial scale. Established tools maker Miltenyi Biotec remains the default choice for many labs' individual instruments. Multiply's pitch is that it automates a customer's entire existing equipment ecosystem inside one closed robotic system rather than one unit operation at a time, but it will need more deals like Retro Biosciences to prove that approach wins against better-funded, more established alternatives.

VC lens

Would YC fund it? Mixed-to-yes: a decade of hardware grind that ended in a real paying commercial contract and a strategic-heavy Series B shows staying power most biotech robotics startups never reach, but the capital intensity and nine-year runway to get here cut against YC's usual speed-to-traction bar.

Biggest risk: Multiply Labs is selling capital equipment into an industry that moves slowly and already has entrenched, well-funded rivals in Cellares and Ori Biotech pursuing the same automation opportunity. If its real-world cost and throughput gains don't clear the bar pharma manufacturers need to switch away from existing contract manufacturers, the company's commercial pipeline beyond its one disclosed deal with Retro Biosciences could stall despite nine years of development and a fresh 75 million dollars in the bank.

Runners-up

Zomint

36 crore rupee seed round led by Lightspeed and Prime Venture Partners for the Bengaluru wealthtech platform giving working professionals and families a dedicated investment adviser and a 25,000 rupee minimum monthly SIP. (Oct 7)

Parakeet Health

10 million dollar Series A led by Canvas Ventures for the AI patient-access platform that automates scheduling, insurance verification and referrals and now says it works with six of the ten largest U.S. dermatology groups. (Oct 1)

OuterSignal

22 million dollar Series A co-led by Long Journey Ventures and Abstract Ventures for the New York startup whose AI agents build customer profiles from commerce and CRM data to personalize marketing for consumer brands. (Sep 30)

Efficient Computer

97 million dollar round led by TQ Ventures at a 650 million dollar valuation for the Carnegie Mellon spinout shipping its Electron E1 dataflow chip, which it says is far more energy-efficient than Intel or Nvidia designs, for drones and small robots. (Sep 29)

Archive

38 reports · click a row to open it

Date	Winner	One-liner	Runners-up
2026-10-19	Modal Labs	750 million dollar Series D led by Accel at a 15.75 billion dollar valuation, as the AI infrastructure startup says its annualized run rate crossed 1 billion dollars with usage tripling in five months, built on serverless GPU access for inference, training and agent sandboxes	OMass Therapeutics, Scanntech, North.cloud, Fortem Technologies
2026-10-18	Mueon	65 million dollar Series A led by Maverick Silicon, as the Portland semiconductor startup founded by two Intel veterans scales Cubelets, modular 3D blocks bundling compute, memory, power and cooling to cut AI data center power and density limits, already in use by AI chip startup d-Matrix	Estuary Biotherapeutics, Fission, Otter Health, HyLight
2026-10-17	Chariot Claims	10 million dollar Series A led by Silverton Partners, as the rebranded ClaimClam legal-tech platform scales automated matching of consumers to mass arbitration and class-action claims over hidden fees and hard-to-cancel subscriptions, building on more than 65,000 claims already processed toward an estimated 92 million dollars in settlements	Marklo, Siena, Rein Security, Peppermint
2026-10-16	Salience Labs	125 million dollar oversubscribed Series B led by Bullhound Capital, as the Oxford-spun-out photonics company wins new backing from AMD Ventures and Intel Capital for all-optical circuit switches meant to break the power and latency ceiling facing electronic switches as AI GPU clusters scale toward tens of thousands of chips	Navra, Type One Energy, Oratomic, Gallatin AI
2026-10-15	Soufflé Therapeutics	135 million dollar Series B led by Juvia Group, as the MIT bioengineer Robert Langer-founded biotech works to deliver RNA medicines to muscle and heart tissue, a problem that has stalled the entire siRNA drug class, backed by more than 3.5 billion dollars in big pharma partnerships before any program has reached the clinic	ICON, Pluto Security, Nous Research, Atomic Machines
2026-10-14	Vitalize	31 million dollar Series A led by Oak HC and FT, as the Y Combinator-backed startup unifying hospital staffing, scheduling, patient flow and capacity management expands after enterprise customers reported cutting manual scheduling work and premium labor spend	Gallatin AI, byteXL, Desible.ai, Credfix
2026-10-13	Universal Quantum	100 million dollar Series A co-led by DCVC and Firgun Ventures, a record raise for a UK quantum computing company, as the University of Sussex spinout races to prove its modular trapped-ion chiplet interconnect can out-scale newly public rivals Quantinuum and IonQ	Atlas Atomics, Type One Energy, Sabi, Catalyst
2026-10-12	Manus	500 million dollar funding round led by Boyu Capital and IDG Capital, the general AI agent's first raise since China blocked Meta's 2 billion dollar bid for the company and barred its founders from leaving the country, as Manus pursues a reported 4 billion dollar valuation on roughly 125 million dollars of annualized revenue	Oratomic, Matchpoint Therapeutics, Oxide Computer, Stuut
2026-10-11	Arena	200 million dollar Series B co-led by Lightspeed Venture Partners and Khosla Ventures at a 3.1 billion dollar valuation, as the company behind the Chatbot Arena leaderboard nearly doubles its valuation in ten months on roughly 100 million dollars of annualized revenue from selling AI evaluation and alignment benchmarking to labs and enterprises, while Scale AI's new Seal Showdown contests its neutral-referee position	Gallatin AI, Rein Security, Rivercell, TeddyHoldings.AI
2026-10-10	Multiply Labs	75 million dollar Series B led by Patrick Soon-Shiong's NantWorks with new investors AstraZeneca, Lingotto, Teradyne and Strange Ventures, as the decade-old biologics-manufacturing robotics company passes 100 million dollars raised on the strength of its first commercial sale, an up to 85 million dollar deal with Retro Biosciences, while competing against well-funded rivals Cellares and Ori Biotech to automate cell and gene therapy production	Zomint, Parakeet Health, OuterSignal, Efficient Computer
2026-10-09	RougeTx	58 million dollar Series A led by BioGeneration Ventures and Angelini Ventures with the European Investment Bank's Aurea facility and Kurma Partners also investing, as the Leiden University Medical Center spinout launches the first disease-modifying candidate for hereditary hemorrhagic telangiectasia, a bleeding disorder with no approved therapies, built on more than two decades of pericyte research	GMI Cloud, Varda Space Industries, doxx.net, Beyond Appliances
2026-10-08	General Medicine	120 million dollar Series B led by Andreessen Horowitz with Eli Lilly and Mercy Health joining, as the PillPack founders' online healthcare marketplace brings total funding to 152 million dollars less than three years after launch on hundreds of thousands of customers and an 80 Net Promoter Score	Noah, Nous Research, Buntar Aerospace, Monid
2026-10-07	Vinci	250 million dollar Series B at a 1.5 billion dollar valuation co-led by Advent, Temasek and Xora Innovation, as the Palo Alto physics foundation model startup jumps from a 46 million dollar seed and Series A disclosed last December to a tenfold valuation leap less than a year later, aiming its technology at chip design incumbents Cadence and Synopsys	Spiko, Hadrian, WhiteLab Genomics, Inbolt
2026-10-06	Pandektes	13.5 million euro Series A led by Munich's Alstin Capital, as the Copenhagen legal-research startup grows revenue sixfold and wins customers switching off LexisNexis, Westlaw, Beck and Karnov with an API-first legal data platform	OneByZero, Fleuret AI, Laki Power, RobCo
2026-10-05	PaleBlueDot AI	200 million dollar Series C at a 3.2 billion dollar valuation led by ComputeCore, as the Palo Alto AI compute platform nearly triples its valuation in under nine months on more than 5 billion dollars of signed customer contracts	Simple Energy, Elio Mortgage, Menos AI, SedMed
2026-10-04	Flow Engineering	50 million dollar Series B at a 750 million dollar valuation co-led by Valor Equity Partners and Atreides Management, as the AI-native systems-engineering platform for hardware teams grows to over 100 million requirements managed and adds General Motors, Anduril and Intuitive Machines as customers less than a year after its Series A	Miter, Kanu AI, Beltic, Satlyt
2026-10-03	EliseAI	350 million dollar round at a 4 billion dollar valuation led by Andreessen Horowitz and Bessemer Venture Partners, as the housing and healthcare conversational AI company nearly doubles its valuation in thirteen months on 200 million dollars of ARR and five straight years of 100 percent revenue growth	Kahua, Breye Therapeutics, Amara, Kuro
2026-10-02	Armadin	255.5 million dollar Series B co-led by Andreessen Horowitz and Accel at a 2.5 billion dollar valuation, as Mandiant founder Kevin Mandia's agentic attacker-swarm security platform runs live attack campaigns for Fortune 500 and government customers seven months after stealth	Foundational, Seeds Fincap, Numeral, Chamelio
2026-10-01	General Intuition	220 million dollar Series B at a 6.2 billion dollar valuation, nearly tripling in three months, as the AI foundation model startup trains action models on billions of gameplay clips from its own sister company Medal	Varda, Jeeves, Sand.ai, Arivihan
2026-09-30	Tiny Health	Oversubscribed $33M Series B led by B Capital as the at-home microbiome testing company posts 1,624% three-year revenue growth and quadruples its practitioner-facing business	Modulate, erad, Baselayer, Ande
2026-09-29	Instinct	$1B Series C led by Sequoia, Benchmark and Coatue at a $10B valuation, a roughly 4x jump in five weeks, as its text-message AI agent passes 100,000 users with 10% daily compounding growth	SiMa.ai, Quartermaster, Outmarket AI, Humanos
2026-09-28	Solcoa Industries	$75M seed ($45M equity led by Bain Capital Ventures plus $30M JPMorgan-anchored debt) to build a 500-tonne Nevada plant using a novel rare-earth metalmaking process, aimed at breaking China's 95% grip on metallization	Clastix, Prevision Medicine, Spiich, Barq
2026-09-27	Ultraviolette	$85M Series E led by Yali Capital and TDK Ventures; Bengaluru performance EV motorcycle maker plans US entry by 2027 on 4-5x revenue growth	Micro1, Kasvu Therapeutics, HIFI, Dextr AI
2026-09-26	Island	$400M Series F led by Evolution Equity Partners at a $6.4B valuation, more than doubling its 2024 valuation as the enterprise browser expands into governing AI agents	Cyera, Confido, Heidi Health, Firecrawl
2026-09-25	Ema	$77M Series B led by Creaegis, more than quadrupling its valuation as every existing backer doubled down and Wipro scales its AI Employees to 240,000+ workers	Ando, Kasvu Therapeutics, HIFI, Nuvah
2026-09-24	TEKEVER	$580M Series D led by UC Investments and Baillie Gifford; Ukraine-proven AI surveillance drone maker hits $6.4B valuation on a new 400M pound UK Army contract	Enveda Biosciences, Basecamp Research, Numeral, Brahma AI
2026-09-23	Verda	$189M oversubscribed Series B led by Emergence Capital; profitable Nordic GPU cloud crosses $1B valuation on $165M ARR	Snorkel AI, Nexstrom, MacroCycle, Demoverse
2026-09-22	BCI-Sonics	RMB 200M (~$30M) Pre-Series A led by HSG and Yunqi Capital; non-invasive ultrasound brain-computer interface racing China's invasive BCI leaders and OpenAI-backed Merge Labs	Spott, HighLife, CellPoint, Benford
2026-09-22	Amber Electric	€49M Series E led by Morgan Stanley's 1GT; automates 50%+ of Australia's home batteries, expanding VPP software into Europe via E.ON	Corridor, Paymob, Unit1 Studio, Drivn
2026-09-18	TypeSafe AI	$40M seed led by DCVC; "System One" model returns typed decisions for software, not chat — built by RLHF co-inventor Diogo Almeida	Space Epoch, Facilo, Treble Technologies, DheyaTech
2026-09-17	Exein	$270M Series C at $1.7B valuation (30x in 2 yrs); kernel-level security layer for robots, drones and autonomous machines	Anew Labs, Delos Data, CADDi, AIUC
2026-09-16	Euclyd	€200M+ Series A; Samsung-backed (investor + manufacturer) AI inference chip built to out-efficiency Nvidia, chaired by ex-ASML CEO	Profound, Flam, ENCOS, Nutshell Therapeutics
2026-09-15	Fortaegis	$50M oversubscribed Series A; quantum-safe security rooted in silicon, chaired by Quantinuum founder Ilyas Khan	Qupital, Tandem Health, Atomarine, UniqYou
2026-09-11	Positron AI	$875M Series C at $5B valuation; memory-first inference chips challenging Nvidia's HBM lock-in	The Boring Company, Mach Industries, Rogo Technologies, Swish
2026-09-10	Cognition AI	$2B+ Series E at $48B valuation; Devin autonomous coding agent nears $900M run-rate	DigitalPaani, Algomatic Dynamics, Limetax, Fundly.ai
2026-09-09	Bluecore Energy	Floating nuclear reactor barges for ports; $50M seed just 2 months after stealth launch	QNu Labs, ARC Ride, Circolife, Hope Care
2026-09-08	Pixxel	$100M Series C, India's largest spacetech round; building orbital AI data centers	Nua, Navana.ai, GalaxEye, Atoms (Kalanick)
2026-09-07	Medulance	GPS-dispatched ambulance network raises ₹24 Cr Series A-2	Comet, Mokobara, Kit (Speakeasy), XDOF

Sources

Compiled from search results: article pages were unreachable from the publishing environment on this date, so every fact here was cross-checked against at least two independent reports.